Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

MISSISSAUGA, ON, May 27 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab. YM anticipates that patients will also begin to be enrolled in the near future in its trial in patients with NSCLC ineligible for curative treatment and who are being treated with radiotherapy palliatively.

The current trial designs were informed by previous trials with nimotuzumab in the same indications. Previous palliative data were presented at ASCO 2008 (Abstract 3037, Bebb, G) and brain metastases randomized data at EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics, 2008 (Poster 505, Macias, A).

YM BioSciences announced on August 10, 2009 that its wholly-owned subsidiary, YM BioSciences USA Inc. (YM-USA) received a license from the US Department of the Treasury's Office of Foreign Assets Control (OFAC) that lifted the limitation on the development of nimotuzumab in the USA for patients with solid tumor cancers.

"The enrollment of the first adult US patient into our nimotuzumab trial in brain metastases from NSCLC is an important milestone for YM, allowing adult US patients the opportunity to receive nimotuzumab and a broader group of US oncologists to gain experience with it," said David Allan, Chairman and CEO of
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... researchers led by Northeastern University has developed a ... and a variety of nanocarbon structures in carbon ... scalable, which will allow the researchers to tailor ... in applications ranging from electronic devices to CNT-reinforced ... sports equipment. , Their findings were published in ...
(Date:9/15/2014)... DUBLIN , Sept. 15, 2014 Research ... "Whole Exome Sequencing Market by Product, by Services, by Technology, ... their offering. Whole Exome Sequencing (WES) is ... the genome, i.e. the exon. The exome, which is the ... of the total genome and is actually converted into proteins ...
(Date:9/15/2014)... , 15 septembre 2014 La ... Week (IPAW) (semaine internationale sur la sensibilisation ... octobre. Initiative conjointe de la Plasma Protein ... sociétés membres , l,IPAW vise à : ... sujet de la collecte du plasma-aphérèse , ...
(Date:9/14/2014)... 2014 UMBC’s Biotechnology Graduate Programs’ ... October 21, 2014, from 12:00 to 1:00 p.m. EDT. ... innovative curriculum and practice-oriented instruction, designed for working professionals. ... help advance their career in the biotechnology industry. , ... , About UMBC’s Biotechnology Graduate Programs, UMBC offers ...
Breaking Biology Technology:Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 2Global Whole Exome Sequencing (Systems, Kits, Library Preparation, Target Enrichment) Market by Product, by Services, by Technology, by Application - Forecast to 2018 3L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2
... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
(Date:9/15/2014)... week,s print issue of the journal Science ... New Mexico, Montana and even the Netherlands, thanks to ... more the norm in these connected times. Yes, the ... produce innovations in biology, medicine, biotechnology and agriculture. It ... talked with that one, that one knew another one, ...
(Date:9/15/2014)... leading coral reef ecologists fears that reef biodiversity may ... that we once thought. , In an international study ... of Excellence for Coral Reef Studies (Coral CoE) says ... species within reef ecosystems. , In coral reefs, just ... that keep the ecosystem safe and functioning. , ...
(Date:9/15/2014)... new strategic vision document, released today by the ... the long-term goals, objectives, and strategies for the ... over the next five years (2015-2020). In ... activities, to be funded in 2015, will include ... fellowships. , The $500 million, 30-year program ...
Breaking Biology News(10 mins):Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
... , , , , , , , ... , , , ... file available on request).,This noisy frog is a potent... , Click here for more ... , , , , , , ...
... with obese children shows that all diets are effective in ... one that accounts for how many carbs are in the ... glucose levels may be most promising. The Cincinnati ... and portion-controlled diets with obese children is published online in ...
... team has identified epigenetic signatures, markers on DNA that ... cells. These signatures can predict the expression of a ... stem cells (iPSCs), cells that take on embryonic stem ... is controlled brings us one step closer to developing ...
Cached Biology News:Common North American frog identified as carrier of deadly amphibian disease 2Common North American frog identified as carrier of deadly amphibian disease 3Common North American frog identified as carrier of deadly amphibian disease 4New study compares diets for weight management in obese children 2Epigenetic signatures direct the repair potential of reprogrammed cells 2
...
... Monoclonal Anti-β-Tubulin IV Recognizes an ... sequence of β-tubulin isotype IV. ... isotypes is observed. ascites fluid ... C-terminal sequence of β-tubulin isotype ...
... Finnpipette BioControl is a major step ... complete liquid handling system - with ... tip cone modules. All five single ... modules fit one handle. The lightweight ...
... the joining of two strands of DNA ... of adjacent nucleotides in either a cohesive-ended ... also been shown to catalyze the joining ... RNA strand in a duplex molecule but ...
Biology Products: